Patient: Participant B
Date of Birth: 01-01-1960

Based on the National Health Guidelines (NHMRC)¹ and the patient’s risk of developing bowel cancer in the next 10 years, they are recommended to have a colonoscopy every 5 years.

The patient’s absolute risk of developing bowel cancer in the next 10 years is 5.3%

This risk was calculated from their DNA test, their family history of bowel cancer, their sex and their age.

This graph shows the patient’s risk of developing bowel cancer over time, compared to the risk of the general Australian population. These recommendations are based on the current best information about the impact of DNA variation on bowel cancer risk and their family history. If their family history of cancer changes, their screening recommendations might need review.

¹ Cancer Council Australia Colorectal Cancer Guidelines Working Party. Clinical practice guidelines for the prevention, early detection and management of colorectal cancer. Sydney: Cancer Council Australia 2018
This diagram shows what would happen to 100,000 people like your patient if they have either a faecal occult blood test (FOBT), no bowel cancer screening or a colonoscopy.

100,000 people have a FOBT
- 8,846 test positive
- 91,154 test negative
- 1,579 have bowel cancer
- 281 have bowel cancer
- 73 die from bowel cancer
- 41 die from bowel cancer

100,000 people have no screening
- 68 perforations
- 140 bleeds
- 8 deaths
- 1,860 have bowel cancer
- 366 die from bowel cancer

100,000 people have a colonoscopy
- 98,233 test negative
- 1,767 have bowel cancer
- 93 have bowel cancer
- 81 die from bowel cancer
- 14 die from bowel cancer

115 DEATHS
12 BLEEDS | 6 PERFORATIONS

366 DEATHS
140 BLEEDS | 68 PERFORATIONS

103 DEATHS

These recommendations are based on the current best information about the impact of DNA variation on bowel cancer risk and the patient’s family history. If their family history of cancer changes, their screening recommendations might need review.

FURTHER INFORMATION
For further information please contact:
Sibel Saya: Study Coordinator & Genetic Counsellor
P: xx xxxx xxxx or E: script-trial@unimelb.edu.au

Victorian Comprehensive Cancer Centre
University of Melbourne, Level 10,
305 Grattan Street, Melbourne 3010
Ethics ID: 2057592.1